Evidence map›Paper›PMID 37630558›Full record

ArticleMicroorganisms2023

Remdesivir: Effectiveness and Safety in Hospitalized Patients with COVID-19 (ReEs-COVID-19)-Analysis of Data from Daily Practice.

Nikos Pantazis, Evmorfia Pechlivanidou, Anastasia Antoniadou, Karolina Akinosoglou, Ioannis Kalomenidis, Garyfallia Poulakou, Haralampos Milionis, Periklis Panagopoulos, Markos Marangos, Ioannis Katsarolis and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Cu(I)-N-Heterocyclic carbenes as potent inhibitors of SARS-CoV-2 replication.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Nikos PantazisDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-4196-5066
Evmorfia PechlivanidouDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-0492-2550
Anastasia Antoniadou4th Department of Internal Medicine, Attikon University General Hospital, Medical School, National & Kapodistrian University of Athens, 12461 Athens, Greece.ORCID 0000-0003-0991-9198
Karolina AkinosoglouDepartment of Internal Medicine, University General Hospital of Patras, Department of Medicine, University of Patras, 26504 Rio, Greece.ORCID 0000-0002-4289-9494
Ioannis Kalomenidis1st Department of Critical Care & Pulmonary Service, Evangelismos General Hospital, Medical School, National & Kapodistrian University of Athens, 10676 Athens, Greece.
Garyfallia Poulakou3rd Department of Internal Medicine, Athens Hospital for Diseases of the Chest "Sotiria", Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece.
Haralampos MilionisDepartment of Internal Medicine, University General Hospital of Ioannina, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0003-3958-2266
Periklis PanagopoulosDepartment of Internal Medicine, University General Hospital of Alexandroupolis, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Markos MarangosDepartment of Internal Medicine, University General Hospital of Patras, Department of Medicine, University of Patras, 26504 Rio, Greece.
Ioannis KatsarolisMedical Affairs, Gilead Sciences Hellas and Cyprus, 17564 Paleo Faliro, Greece.
Pinelopi Kazakou4th Department of Internal Medicine, Attikon University General Hospital, Medical School, National & Kapodistrian University of Athens, 12461 Athens, Greece.
Vasiliki DimakopoulouDepartment of Internal Medicine, University General Hospital of Patras, Department of Medicine, University of Patras, 26504 Rio, Greece.
Anna-Louiza ChaliasouCOVID-19 Unit, Evangelismos General Hospital, 10676 Athens, Greece.
Vasiliki Rapti3rd Department of Internal Medicine, Athens Hospital for Diseases of the Chest "Sotiria", Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece.
Eirini ChristakiDepartment of Internal Medicine, University General Hospital of Ioannina, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
Angelos LiontosDepartment of Internal Medicine, University General Hospital of Ioannina, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0002-0361-0846
Vasileios PetrakisDepartment of Internal Medicine, University General Hospital of Alexandroupolis, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Georgios SchinasDepartment of Internal Medicine, University General Hospital of Patras, Department of Medicine, University of Patras, 26504 Rio, Greece.ORCID 0000-0001-7963-1865
Dimitrios BirosDepartment of Internal Medicine, University General Hospital of Ioannina, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
Maria-Christina RimpaDepartment of Internal Medicine, University General Hospital of Alexandroupolis, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Giota TouloumiDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-5951-0844
National and Kapodistrian University of Athens · GRUniversity of Ioannina · GRUniversity of Patras · GRDemocritus University of Thrace · GREvangelismos Hospital · GR

Funding

Gilead Sciences, Inc. CO-GR-540-6245
6 · The paper itself

Abstract

Remdesivir was the first antiviral approved for treating COVID-19. We investigated its patterns of use, effectiveness and safety in clinical practice in Greece. This is a retrospective observational study of hospitalized adults who received remdesivir for COVID-19 in September 2020-February 2021. The main endpoints were the time to recovery (hospital discharge within 30 days from admission) and safety. The "early" (remdesivir initiation within 24 h since hospitalization) and "deferred" (remdesivir initiation later on) groups were compared. One thousand and four patients (60.6% male, mean age 61 years, 74.3% with severe disease, 70.9% with ≥1 comorbidities) were included, and 75.9% of them were on a 5-day regimen, and 86.8% were in the early group. Among those with a baseline mild/moderate disease, the median (95% CI) time to recovery was 8 (7-9) and 12 (11-14) days for the early and deferred groups, respectively (

Indexed as

COVID-19effectivenesshospitalized patientsremdesivirsafety

Identifiers

PMID37630558
PMCPMC10459397
OpenAlexW4385557130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.